

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31220X2C2-R1	SERIAL NO. 10/024,858
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Leonard, et al.	
		FILING DATE December 18, 2001	GROUP 1615

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>JS</i>	AF	5, 322, 697	06/21/1994	Meyers	—	—	
<i>JS</i>	AG	5, 284, 662	02/08/1994	Koparkar, et al.	—	—	
<i>JS</i>	AH	4, 851, 228	07/25/1989	Zentner, et al.	—	—	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	<i>JS</i>	BF	0 839 039	05.11.2003	EP			
	<i>JS</i>	BG	0 546 593	23.10.1992	EP			
	<i>JS</i>	BH	WO 92/19226	12.11.1992	WIPO			
	<i>JS</i>	BI	WO 93/24154	09.12.1993	WIPO			
	<i>JS</i>	BJ	0 654 263	17.11.94	EP			

NOT
PRIOR
ART

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>JS</i>	CG	Opposition to European Patent No. EP 0839039, (Aug. 5, 2004) by Solvay Pharmaceuticals, Netherlands.
	CH	Opposition to European Patent No. EP 0839039. (Aug. 4, 2004) by Dragotti & Associati SRL, Italy.
	CI	Aulton, Ed., "Pharmaceutics: The Science of Dosage form Design", pp 204-211, Churchill Livingstone, Edinburgh (1988)
	CJ	Leonard; <i>J Clin Psychiatry</i> , 1993 Aug; 54 Suppl: 3-15; discussion.
	CK	Leonard; <i>Drugs</i> 1992; 43 Suppl 2:3-9; discussion 9-10.
	CL	Jenner ; <i>Int Clin Psychopharmacol</i> . 1992 Jun; 6 Suppl 4: pp. 69-80.
	CM	De Wilde et al., <i>Acta Psychiatr Scand</i> . 1993 Feb; 87(2): pp. 141-5.
	CN	Boyer & Feighner; <i>J Clin Psychiatry</i> , 1992 Feb; 53 Suppl: pp. 3-6.
	CO	Dechant & Clissold; <i>Drugs</i> 1991 Feb; 41(2): pp. 225-53.
	CP	Lucchelli et al., <i>Br J Pharmacol</i> ., 1995 Mar; 114(5): pp. 1017-25.
	CQ	Sanger & McClelland ; <i>Eur J Pharmacol</i> . 1986 Aug 15; 127(3): pp. 179-85.
	CR	Chambliss et al., <i>J Pharma Sci</i> . 1984 Sep; 73(9): pp. 1215-9.
	CS	Ryan et al., <i>Clin Pharmacol Ther</i> . 1987 Jul; 42(1): pp. 28-32.
	CT	Hawthorne et al., <i>Br J Clin Pharmacol</i> . 1991 Jul; 32(1): pp. 77-83.
	CU	Aabakken et al., <i>Scand J Gastroenterol Suppl</i> . 1989; 163: pp. 65-73.
	CV	Florence & Jani ; <i>Drug Saf</i> . 1994 Mar; 10(3): pp. 233-66.
	CW	Mori et al., <i>J Pharm Sci</i> 1991 Sep; 80(9): pp. 876-80.
<i>JS</i>	CX	Lucker et al., <i>Arzneimittelforschung</i> . 1982; 32(4): pp. 409-13.



Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31220X2C2-R1	SERIAL NO. 10/024,858
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Leonard, et al.	
		FILING DATE December 18, 2001	GROUP 1615

OTHER DOCUMENTS, CONT. (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>JS</i>	CY	Fara et al., Pharm Res. 1988 Mar; 5(3): pp. 165-71.
<i>JS</i>	CZ	Perucca et al, Clin Pharmacokinet (1994) 27(3): pp.175-190.
<i>JS</i>	CAA	ABPI Data Sheet Compendium 1988-89, pp. 445-6.
<i>JS</i>	CAB	Freeman, J Psychiatr Neurosci, vol 16 no 2 (Suppl 1), 1991
EXAMINER <i>Sumera H. Sheikh</i> DATE CONSIDERED <i>1/4/05</i>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

n:\wjd\paroxetine\p31220x2c2-r1-ptol449.doc